ALK and non-small cell lung carcinoma: According to clinical guidelines from the European Society for Medical Oncology (ESMO), the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN), and Guidelines of the Chinese Society of Clinical Oncology (CSCO) for NSCLC, first-line treatment for patients with ALK gene mutations includes ceritinib, alectinib, brigatinib, lorlatinib, and these are all prioritized (Lee et al., 2024; Riely et al., 2024; Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care, 2024).